{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-010792","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2025-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.057829+00:00","generated_at":"2026-05-17T06:34:55.103830+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tenax Therapeutics receives EPO intention to grant patent for levosimendan in PH-HFpEF through 2040","bullets":["EPO intends to grant patent covering TNX-103 (oral levosimendan) and other formulations for PH-HFpEF.","European patent protection through at least December 2040, with potential SPC extension beyond.","Patent also covers active metabolites OR1896/OR1855 and combination with other cardiovascular drugs.","Builds on existing U.S. and Canada patents; supports Phase 3 LEVEL-2 study initiation expected this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-010792","json":"https://secwatch.observer/filing/0001654954-25-010792.json","markdown":"https://secwatch.observer/filing/0001654954-25-010792.md","text":"https://secwatch.observer/filing/0001654954-25-010792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495425010792/0001654954-25-010792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495425010792/tennx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:34:55.103830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}